Angelika Irmler

Title: Angelika Irmler: Innovator in Vaccine Development

Introduction

Angelika Irmler is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of vaccine development, particularly in relation to Zika virus and purification strategies for viruses. With a total of 2 patents, her work is paving the way for advancements in immunogenic compositions.

Latest Patents

Irmler's latest patents include innovative approaches to recombinant Zika vaccines. The first patent focuses on immunogenic or vaccine compositions that comprise at least one recombinant Zika virus antigen. This antigen is encoded by nucleic acid sequences that relate to the E-protein of the Zika virus. The invention also includes methods for purifying recombinant chimeric virus particles, which are essential for creating effective vaccine compositions.

The second patent addresses chromatography-based purification strategies for large and pleomorphic infectious virus particles. This invention aims to reduce the content of contaminating host cell DNA and other impurities in vaccine preparations. The methods developed by Irmler are crucial for producing immunogenic compositions suitable for vaccination treatments.

Career Highlights

Angelika Irmler is currently associated with Themis Bioscience GmbH, where she continues her research and development efforts. Her work is characterized by a commitment to improving vaccine efficacy and safety.

Collaborations

Irmler collaborates with notable colleagues, including Matthias Müllner and Erich Tauber. These partnerships enhance her research capabilities and contribute to the success of her innovative projects.

Conclusion

Angelika Irmler is a key figure in the field of vaccine innovation, with her patents reflecting her dedication to advancing public health. Her contributions are vital in the ongoing fight against infectious diseases.